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The systemic effects of local 
infiltrations with corticosteroids. 
Implications for palliative care?
Abstract
Corticosteroids are used in approximately 50% of palliative care patients. Increasingly corticosteroids are 
used as local infiltrations together with local anaesthetics. This treatment may be adjuvant to other meas-
ures to control pain. Depo preparations, although their main activity is topical, may also exercise systemic 
toxicity. This may include transient suppression of adrenal activity which may be exacerbated by the use 
of morphine. Some women in reproductive age may experience vaginal blood loss between the periods. 
Other toxicities are rare.
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How do they work?
General idea is that topical corticosteroids work 
topically where there is an irritation or inflammation. 
However, newer data suggest that topical corticos-
teroids acts through inhibition of local discharges by 
the damaged nerve, independent of the anti-inflam-
matory effect [11]. Drugs absorbed from the site of 
infiltration are detectable in plasma during first until 
second weeks [12]. The pain controlling effect may 
be much longer than that and may be sustained for 
many months after infiltration. On the other hand 
preparations for topical infiltrations when injected 
intramuscularly in higher doses, far from the painful 
site, may also have some systemic effect on pain [13]. 
On the other hand the effect of topical corticosteroid 
infiltration can be additive to the effect of systemic 
steroids. When identified a local painful spot in a pa-
tient on systemic corticosteroids, it is still worth to 
try infiltration. (Z. Zylicz, unpublished).
Introduction
Corticosteroids are used frequently in Palliative 
Care. Approximately 30-50% of patients cared 
for their terminal disease are prescribed corti-
costeroids [1]. There are many indications to use 
steroids in palliative care [2]. Whereas most of 
the steroids are used systemically, topical steroid 
infiltrations are used increasingly as an adjuvant in 
pain control [3–8]. We reported successful treat-
ment with corticosteroid infiltrations in terminally 
ill patients several times in this journal [9, 10]. 
The idea to use topical, rather than systemic cor-
ticosteroids is to deliver high concentration of the 
drug locally with a minimum of systemic toxicity. 
This approach is usually successful; however, clini-
cians should be aware of systemic toxicity as it may 
contribute to patient’s morbidity. In this article we 
analyse the literature and comment on systemic 
effects of topical corticosteroid use.
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Pharmacokinetics and 
pharmacodynamics of topical steroids 
Insoluble preparations absorb slower than the 
more soluble. Triamcinolone acetonide is absorbed 
much more rapidly than triamcinolone hexacetonide 
[12, 14]. Plasma levels of the injected drugs peak 
within 24 hours and significant plasma levels are 
maintained for 1–2 weeks [12]. Suppression of hy-
pophysis-adrenal axis is observed also in the same 
time period. 
Toxicity of the topical steroids
Triamcinolone hexacetonide may in comparison 
to triamcinolon acetonide cause more prolonged 
adrenal suppression and hence be more dangerous in 
long term. Adrenals of most of the patients recover 
spontaneously after couple of weeks [15, 16]. De-
pression may be more permanent when the injec-
tions are repeated couple of times. Not the dose, 
but long time exposure to the drug warrants adrenal 
suppression [17]. Most of the adrenal depression 
is never diagnosed. However, patients with sub-
clinical adrenal insufficiency may suffer symptoms of 
relative adrenal insufficiency during infections. In the 
context of Palliative Care it is possible that this effect 
may contribute to patients’ earlier death. 
Adrenal suppression may be more pronounced or 
even less reversible in patients using opioids and suf-
fering of opioid induced hypogonadism [18]. Special 
care should be taken, when local infiltrations with 
corticosteroids are offered to the patients with 
pre-existing adrenal failure, like in patients who 
previously used glucocorticoids for long time and 
discontinued them, but also those with adrenal 
carcinomas or adrenal metastases of (for example) 
lung cancer.
Glucocorticoid effect of topical steroids may oc-
casionally result in a Cushing syndrome. Couple of 
these patients were described in the past [19].
Other relevant toxicity is the (usually mild) in-
crease of plasma glucose levels in patients with 
known diabetes mellitus, or occasionally in an ap-
parently healthy person. The effect is usually limited 
to the first two weeks after infiltration. 
Woman in a reproductive age may suffer of 
vaginal blood loss between the periods after 
local infiltration with Depo steroids; and they 
should be warned about this before treatment. 
Although this toxicity is mentioned in drugs licence 
I was unable to trace the appropriate literature 
about this. Personally, I recall one female patient, 
aged 45, with an advanced metastatic carcinoma 
of unknown primary who did not menstruate for 
9 months, but experienced severe vaginal blood 
loss after successful treatment of her localised pain 
with 80 mg of methylprednisolone acetate. Blood 
loss was successfully treated with tranexamic acid 
[20]. The gynaecologist excluded any intrauterine 
pathology. Next time she came for infiltration, 
vaginal blood loss could be anticipated and blood 
loss was limited.
Injecting depo steroids (as in Depo Medrol®) 
into the soft tissues other than peritoneal, pleural or 
joint cavities, may be painful. Most probably benzyl 
alcohol, used as preservative, is responsible for pain 
on injection. Therefore it is a good practice to dilute 
the drug with for example local anaesthetic like 
bupivacaine. Local pain after injection could also be 
due to local sensitisation and allergic reaction [21]. 
This is probably rare. 
Polymorphism of the glucocorticoids receptor 
gene may result in abnormal sensitivity to corticos-
teroids [22]. Patients with this abnormality tend to 
have increased BMI and decreased bone minerali-
sation with normal plasma cortisol levels. In these 
patients effects of topical steroids, as well as their 
toxicity may be increased.
Finally, although extremely rare, locally injected 
corticosteroids are able to produce psychosis, which 
may be difficult to be recognised and treated [23]. 
Local atrophy of the subcutaneous tissues had been 
described in several patients after infiltration with 
depo steroids [24].
Conclusions
Depo corticosteroids like triamcinolone aceton-
ide or methylprednisolone acetate may be useful in 
the treatment of some conditions in palliative care. 
Although the drugs are injected locally and exercise 
their effect locally, their toxicity may be systemic. 
Especially the first two weeks after injection pa-
tients are prone to adrenal suppression which may 
blunt hormonal stress response during infection. 
Other toxicities may be rare, but significant in Pal-
liative Care population. 
Some patients may be more susceptible for ster-
oid toxicity and they either should be warned about 
this or the treatment should be postponed. To the 
first category belong female patients in a reproduc-
tive age, to the second patients with adrenal primary 
tumours or metastases.
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